Pneumococcal conjugate second or third-dose vaccines (PCVc) in Australia
Australia: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 94.0% in 2025. ▲ Rising
Latest (2025)
94.0%
Change on year
down 1.1%
World rank
46th
of 194 countries
All-time high
97.0%
in 2020
All-time low
91.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Australia, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Australia stood at 94.0%.
That represents a change of down 1.1% on the previous year and up 1.1% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Australia peaked at 97.0% in 2020 and was at its lowest, 91.0%, in 2008.
Australia ranks 46th of 194 countries on this measure, in the top quarter.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Australia, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 91.0% | — |
| 2009 | 91.0% | +0.0% |
| 2010 | 91.0% | +0.0% |
| 2011 | 91.0% | +0.0% |
| 2012 | 91.0% | +0.0% |
| 2013 | 91.0% | +0.0% |
| 2014 | 91.0% | +0.0% |
| 2015 | 93.0% | +2.2% |
| 2016 | 94.0% | +1.1% |
| 2017 | 94.0% | +0.0% |
| 2018 | 95.0% | +1.1% |
| 2019 | 96.0% | +1.1% |
| 2020 | 97.0% | +1.0% |
| 2021 | 96.0% | -1.0% |
| 2022 | 96.0% | +0.0% |
| 2023 | 95.0% | -1.0% |
| 2024 | 95.0% | +0.0% |
| 2025 | 94.0% | -1.1% |
Australia compared with similar countries
- Australia's 94.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
- Australia's 94.0% is above the median for East Asia & Pacific, which is 81.0%, 1.2× the median. (30 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 91.0% | 91.0% | 91.0% | 2 |
| 2010s | 92.7% | 91.0% | 96.0% | 10 |
| 2020s | 95.5% | 94.0% | 97.0% | 6 |
Countries ranked near Australia
More health data for Australia
- Un projection of annual infant deaths, annual growth rate -1.83 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.9072 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 906.6 deaths per 1,000 people (2090)
- Number of infants who die before age 1 215 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate 1.45 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0279 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.35 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Australia?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Australia was 94.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Australia?
- The highest recorded value was 97.0% in 2020.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Australia?
- The lowest recorded value was 91.0% in 2008.
- How does Australia rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Australia ranks 46th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Australia?
- Over the last ten years it is up 1.1%. The long-run trend across the full record is rising.
- Where does this Australia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).